 Lasmiditan is a selective 5-HT1F agonist that is under development by Eli Lilly and Company for the treatment of migraine.Serotonergic psychedelics like psilocybin, LSD, and mescaline act as 5-HT2A receptor agonists.Their actions at this receptor are thought to be responsible for their hallucinogenic effects.